Microdosing Ketamine and Cognitive Function
Microdosing ketamine is not recommended for cognitive enhancement or any psychiatric indication outside of supervised clinical settings, as there is no established safety data for long-term low-dose ketamine use, and FDA-approved ketamine dosing is only for anesthesia at much higher doses (1-4.5 mg/kg IV). The concept of "microdosing" ketamine lacks regulatory approval, standardized protocols, and safety evidence for chronic administration.
Critical Safety Concerns
The FDA-approved ketamine formulations are exclusively indicated for anesthesia induction and maintenance at subanesthetic doses starting at 1-2 mg/kg IV 1. There is no FDA-approved microdosing regimen for ketamine. The drug labels make no mention of chronic low-dose administration patterns.
Long-Term Safety Remains Unknown
The most significant concern with ketamine microdosing is the complete absence of long-term safety data for regular, ongoing use. While occasional high-dose psychedelic use appears physiologically safe, chronic administration of serotonin 2B receptor agonists (which ketamine affects) has been associated with valvular heart disease 2. This risk has not been directly tested in humans using chronic ketamine microdosing protocols, but the theoretical concern is substantial enough to warrant extreme caution.
Cognitive Effects at Therapeutic Doses
Research on cognitive function has focused on subanesthetic ketamine infusions (0.5 mg/kg IV) for treatment-resistant depression, not microdosing:
Acute effects (2 hours post-infusion): Ketamine causes transient declines in attention, executive function, and verbal memory 3. The magnitude of attention impairment is significantly larger in psychiatric patients compared to healthy controls.
Short-term effects (1-14 days): Cognitive function returns to baseline or slightly improves, particularly in sustained attention and response control 4, 5. These improvements appear linked to reduction in depressive symptoms rather than direct cognitive enhancement.
Repeated infusions: Seven ketamine infusions over a treatment course showed improvements in attention, working memory, and verbal/visuospatial memory (effect sizes d=0.37-0.79), but only verbal memory improvement remained significant after controlling for depression reduction 4.
Key Caveat
All cognitive improvements observed in research studies occurred in the context of treating severe depression, where baseline cognitive function was impaired by the psychiatric illness itself 6. There is no evidence that ketamine enhances cognition in healthy individuals or at "microdose" levels.
Why Microdosing Ketamine Is Problematic
The systematic review on psychedelic microdosing explicitly states that "long-term safety and efficacy remain unknown" for regular microdosing practice 2. The research identifies several critical gaps:
- No controlled studies have examined sustained microdosing patterns that mirror real-world use (daily or every-few-days dosing over months)
- Bidirectional effects are common—the same dose can increase or decrease various measures depending on individual factors
- Response prediction is poor, making it impossible to identify who might benefit versus experience harm
Clinical Bottom Line
Do not recommend or prescribe ketamine for microdosing purposes. If a patient is considering ketamine for psychiatric indications:
- Refer to specialized ketamine clinics that use evidence-based protocols (0.5 mg/kg IV infusions) with appropriate monitoring
- Screen for cardiovascular risk factors given theoretical concerns about chronic serotonin 2B receptor activation
- Assess for substance use disorder risk, as ketamine has abuse potential
- Monitor cognitive function if treatment proceeds, particularly attention and executive function in the acute period post-administration
The Australian and New Zealand psychiatric guidelines emphasize that ketamine use should occur within structured clinical frameworks with appropriate patient selection and monitoring 7. Self-administered microdosing falls far outside these parameters and carries unknown risks that cannot be justified by current evidence.